Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys Zoetis (ZTS) Stock

Democratic Representative Gilbert Ray Cisneros Jr. bought shares of animal health company Zoetis Inc. ZTS on June 16, 2026. According to a periodic transaction report filed under the STOCK Act on July 2, 2026, the trade was valued between $1,001 and $15,000.

Inside Rep. Cisneros's Zoetis Trade

The Democratic lawmaker from California's 31st district executed the purchase while the stock closed at $79.33 on the day of the trade. Because the transaction was reported via a House disclosure form, the exact share count and precise dollar amount remain undisclosed, leaving the value within the standard reporting range.

Other Institutional Activity in Zoetis Inc.

Large investment firms continue to adjust their holdings in the veterinary medicine provider. Smead Capital Management grew its holdings by 347,786 shares, ending with 1,580,996 shares worth about $110.4 million. Nordea Investment Management AB added 727,295 shares, finishing with 6,592,578 shares valued at roughly $523.3 million. Deutsche Bank AG grew its stake by 319,749 shares to reach 5,851,737 shares worth about $464.5 million. Meanwhile, State Farm Mutual Automobile Insurance Co kept its stake steady at 15,892,903 shares valued around $1.26 billion. Guyasuta Investment Advisors exited its position entirely by selling all 4,210 of its shares.

Zoetis Inc. Stock Up 4.9%

The shares recently traded near $78.97, which sits below the event-day close and roughly 46.7% under the 52-week high of $148.30. The stock trades above its 50-day moving average of $73.86 but remains below its 200-day moving average of $96.34.

Recent Earnings

Zoetis reported trailing-twelve-month revenue of $9.53 billion alongside earnings of $6.16 per share. The company delivered a net profit margin of 27.7% and a return on equity of 64.9%. Revenue contracted slightly year-over-year by 0.2%. Investors look ahead to the next financial results release scheduled for November 5, 2026.

Dividend

The company distributes an annual dividend yielding 2.7% with a payout ratio of 33.9%.

Insider Buying and Selling at Zoetis Inc.

Company insiders made notable open-market purchases in May ahead of the representative's trade. Director Michael B. McCallister bought 3,000 shares on May 11, 2026, at an average price of $77.76 for a total value of $233,273. Director Paul M. Bisaro picked up 2,000 shares on May 13, 2026, at $75.88 per share totaling $151,750. Frank A. D. Amelio acquired 6,650 shares on May 13, 2026, at an average price of $75.39 for a total of $501,344.

Analysts Set New Price Targets

Wall Street firms updated their outlooks following earnings reports. UBS maintained a neutral rating with a target of $80.00. JP Morgan kept an overweight rating with a target of $115.00. Piper Sandler maintained a neutral rating with a target of $80.00. Citigroup held a buy rating with a price target of $96.00. BNP Paribas kept an outperform rating with a target of $110.00. Overall, analysts maintain a consensus buy recommendation on the stock with a mean price target of $93.47 across 15 analyst opinions.

About Zoetis Inc.

Headquartered in Parsippany, New Jersey, Zoetis focuses on animal health products. The enterprise develops and manufactures medicines, vaccines, and diagnostic tools for both livestock and companion animals like dogs, cats, and horses.

Bottom Line

The disclosure provides a look into congressional portfolio adjustments. Market participants will monitor upcoming earnings reports and future financial disclosures for further insights into institutional and insider sentiment.